Helicobacter pylori and gastric mucosa-associated lymphoid tissue (MALT) lymphoma: Updated review of clinical outcomes and the molecular pathogenesis

Hidekazu Suzuki, Yoshimasa Saito, Toshifumi Hibi

研究成果: Article

33 引用 (Scopus)

抄録

In most H. pylori-positive patients, gastric low-grade mucosa-associated lymphoid tissue (MALT) lymphomas regress both endoscopically and histopathologically after H. pylori eradication, but no factors that can be predictive of the response to the eradication have been definitively identified, and there is little information on how to determine the optimal observation period before additional treatment can be started. Here, clinical studies dealing with the diagnosis and treatment of gastric MALT lymphomas and H. pylori published during the last 5 years were systematically reviewed, and studies identifying the molecular approaches involved in the pathogenesis were summarized. Most of the clinical studies indicate a favorable effect of H. pylori eradication on the clinical outcome of gastric MALT lymphomas. Some studies suggest the necessity of additional treatment in nonresponders to H. pylori eradication, while others suggest the adoption of a watch-and-wait strategy. The molecular characteristics of MALT lymphomas could play an important role in prognostic prediction and the selection of further therapeutic intervention after the eradication. This updated review of gastric MALT lymphomas illustrates the potential efficacy of H. pylori eradication in tumor remission, but further molecular characterization is necessary to establish the most suitable therapeutic strategy for patients who do not respond to eradication.

元の言語English
ページ(範囲)81-87
ページ数7
ジャーナルGut and Liver
3
発行部数2
DOI
出版物ステータスPublished - 2009 6

Fingerprint

Marginal Zone B-Cell Lymphoma
Gastric Mucosa
Helicobacter pylori
Therapeutics
Non-Hodgkin's Lymphoma
Stomach
Observation
Neoplasms

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

これを引用

@article{1385dae2802445f1b823c1611bed9878,
title = "Helicobacter pylori and gastric mucosa-associated lymphoid tissue (MALT) lymphoma: Updated review of clinical outcomes and the molecular pathogenesis",
abstract = "In most H. pylori-positive patients, gastric low-grade mucosa-associated lymphoid tissue (MALT) lymphomas regress both endoscopically and histopathologically after H. pylori eradication, but no factors that can be predictive of the response to the eradication have been definitively identified, and there is little information on how to determine the optimal observation period before additional treatment can be started. Here, clinical studies dealing with the diagnosis and treatment of gastric MALT lymphomas and H. pylori published during the last 5 years were systematically reviewed, and studies identifying the molecular approaches involved in the pathogenesis were summarized. Most of the clinical studies indicate a favorable effect of H. pylori eradication on the clinical outcome of gastric MALT lymphomas. Some studies suggest the necessity of additional treatment in nonresponders to H. pylori eradication, while others suggest the adoption of a watch-and-wait strategy. The molecular characteristics of MALT lymphomas could play an important role in prognostic prediction and the selection of further therapeutic intervention after the eradication. This updated review of gastric MALT lymphomas illustrates the potential efficacy of H. pylori eradication in tumor remission, but further molecular characterization is necessary to establish the most suitable therapeutic strategy for patients who do not respond to eradication.",
keywords = "API2-MALT1 fusion, BCL10, CD20, Eradication, Helicobacter pylori",
author = "Hidekazu Suzuki and Yoshimasa Saito and Toshifumi Hibi",
year = "2009",
month = "6",
doi = "10.5009/gnl.2009.3.2.81",
language = "English",
volume = "3",
pages = "81--87",
journal = "Gut and Liver",
issn = "1976-2283",
publisher = "Joe Bok Chung",
number = "2",

}

TY - JOUR

T1 - Helicobacter pylori and gastric mucosa-associated lymphoid tissue (MALT) lymphoma

T2 - Updated review of clinical outcomes and the molecular pathogenesis

AU - Suzuki, Hidekazu

AU - Saito, Yoshimasa

AU - Hibi, Toshifumi

PY - 2009/6

Y1 - 2009/6

N2 - In most H. pylori-positive patients, gastric low-grade mucosa-associated lymphoid tissue (MALT) lymphomas regress both endoscopically and histopathologically after H. pylori eradication, but no factors that can be predictive of the response to the eradication have been definitively identified, and there is little information on how to determine the optimal observation period before additional treatment can be started. Here, clinical studies dealing with the diagnosis and treatment of gastric MALT lymphomas and H. pylori published during the last 5 years were systematically reviewed, and studies identifying the molecular approaches involved in the pathogenesis were summarized. Most of the clinical studies indicate a favorable effect of H. pylori eradication on the clinical outcome of gastric MALT lymphomas. Some studies suggest the necessity of additional treatment in nonresponders to H. pylori eradication, while others suggest the adoption of a watch-and-wait strategy. The molecular characteristics of MALT lymphomas could play an important role in prognostic prediction and the selection of further therapeutic intervention after the eradication. This updated review of gastric MALT lymphomas illustrates the potential efficacy of H. pylori eradication in tumor remission, but further molecular characterization is necessary to establish the most suitable therapeutic strategy for patients who do not respond to eradication.

AB - In most H. pylori-positive patients, gastric low-grade mucosa-associated lymphoid tissue (MALT) lymphomas regress both endoscopically and histopathologically after H. pylori eradication, but no factors that can be predictive of the response to the eradication have been definitively identified, and there is little information on how to determine the optimal observation period before additional treatment can be started. Here, clinical studies dealing with the diagnosis and treatment of gastric MALT lymphomas and H. pylori published during the last 5 years were systematically reviewed, and studies identifying the molecular approaches involved in the pathogenesis were summarized. Most of the clinical studies indicate a favorable effect of H. pylori eradication on the clinical outcome of gastric MALT lymphomas. Some studies suggest the necessity of additional treatment in nonresponders to H. pylori eradication, while others suggest the adoption of a watch-and-wait strategy. The molecular characteristics of MALT lymphomas could play an important role in prognostic prediction and the selection of further therapeutic intervention after the eradication. This updated review of gastric MALT lymphomas illustrates the potential efficacy of H. pylori eradication in tumor remission, but further molecular characterization is necessary to establish the most suitable therapeutic strategy for patients who do not respond to eradication.

KW - API2-MALT1 fusion

KW - BCL10

KW - CD20

KW - Eradication

KW - Helicobacter pylori

UR - http://www.scopus.com/inward/record.url?scp=67649289709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649289709&partnerID=8YFLogxK

U2 - 10.5009/gnl.2009.3.2.81

DO - 10.5009/gnl.2009.3.2.81

M3 - Article

C2 - 20431728

AN - SCOPUS:67649289709

VL - 3

SP - 81

EP - 87

JO - Gut and Liver

JF - Gut and Liver

SN - 1976-2283

IS - 2

ER -